Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review)
Frontiers in Oncology · 13.04.2026 · 16
DOI: 10.3389/fonc.2026.1763359 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 13.04.2026. Verfasst von Farid Rajaee Rizi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Precision oncology in urology increasingly depends on integrating heterogeneous data, including multiparametric imaging, histopathology, genomics, and clinical variables. Multimodal artificial intelligence (AI) offers a unified framework to manage this complexity, supporting refined risk stratification, personalized treatment decisions, and informed patient counseling. This narrative review examines applications of multimodal AI in prostate, bladder, and kidney cancers. Beyond listing individual tools, we emphasize how synergistic data fusion enhances the validation of diagnostic and prognostic performance. Clinical advances include more accurate tumor delineation on multiparametric MRI and predictive modeling of functional outcomes after surgery, underscoring the translational potential of these systems. However, major barriers hinder clinical adoption. Prospective validation remains scarce, data harmonization across institutions are limited, and the opaque nature of many algorithms fuels skepticism among clinicians. These factors collectively restrict the integration of multimodal AI into routine clinical practice. Closing this gap requires standardized data curation, development of interpretable and transparent models, and the design of collaborative human–AI workflows. Ultimately, successful translation will depend not only on technical progress but also on redefining trust and expertise in urologic oncology, ensuring that algorithmic insights are meaningfully aligned with bedside decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Urology, Al-Zahra University-Affiliated Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Genetics, Faculty of Natural Sciences, Tabriz University, Tabriz, Iran.
- Department of Urology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Computer Engineering, Faculty of Engineering, Graduate School of Natural and Applied Sciences, Gazi University, Ankara, Türkiye.
Zitieren
APA
Rajaee Rizi, F., Jamadi, M. S., Rahimi, S., Bighamian, M., Paidar, P., Taki, M. J., & Bahmaie, N. (2026). Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review). Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1763359
Vancouver
Rajaee Rizi F, Jamadi MS, Rahimi S, Bighamian M, Paidar P, Taki MJ, et al. Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review). Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1763359
BibTeX
@article{RajaeeRizi2026,
author = {Rajaee Rizi, Farid and Jamadi, Maryam Sadat and Rahimi, Samin and Bighamian, Moein and Paidar, Pouya and Taki, Mohammad Javad and Bahmaie, Nazila},
title = {Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review)},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1763359}
}
EUVIMED